|
KMID : 1035620210090030180
|
|
Allergy Asthma & Respiratory Disease
2021 Volume.9 No. 3 p.180 ~ p.183
|
|
|
Type 2 hereditary angioedema treated with acute exacerbation with icatibant: A case report
|
|
Hwang Yu-Kyoung
An Kyeong-Min
Kim Yong-Hyun
Kim Sae-Hoon
Chang Yoon-Seok
|
|
|
Abstract
|
|
|
|
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by genetic deficiency or decreased function of C1-esterase inhibitor. It is characterized by swelling of subcutaneous and submucosal tissues of the extremities, gastrointestinal tract, and upper airways which can be life-threatening. Thus, early recognition and treatment of the disease are important. Short- and long-term prophylaxes are used to decrease the severity and frequency of attacks. Icatibant is a selective bradykinin B2-receptor antagonist, earlier treatment of acute attacks and hospital admission. The authors present a case of 47-year-old woman who was diagnosed with type II HAE, danazol as a long term. Her symptoms improved dramatically after drug treatment. The unpredictability and recurrence of HAE attacks could have a negative impact on social life and quality of life. This case shows that timely and proper treatment could improve quality of life and reduce morbidity and mortality.
|
|
|
KEYWORD
|
|
|
Hereditary angioedema, Icatibant, Bradykinin B2 receptor antagonist
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|